Reportlinker.com announces that a new market research report related to the Healthcare industry is available in its catalogue.
Forecast Insight: Antihypertensives Key patent expiries prevent market growth
http://www.reportlinker.com/p092392/Forecast-Insight-Antihypertensives–Key-patent-expiries-prevent-market-growth.html
Introduction
Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis’s Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer’s Norvasc and Merck’s Cozaar, will restrain market growth.
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
SWOT Analysis - To Make Your Business More Profitable
The Secrets Of The Winning Jobseeker
Scope
- Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.
- Definition of the unmet needs in the antihypertensives market.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan. neurontin.
- Analysis of major events and brand dynamics affecting the hypertension market.
Highlights
The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.
Cozaar’s and Diovan’s patent expiries in the US have the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve moderate sales and together with Exforge form a potential for market expansion. This however will be set back by the premature expiry of Pfizer’s Norvasc patent.
Reasons to Purchase
- Quantify the future size of the antihypertensives market and identify opportunities for new products.
- Learn how recent changes related to product expiries will shape the antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.